Kinloch Capital’s Olema Pharmaceuticals OLMA Stock Holding History

Kinloch Capital’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-500	Closed	-$24K	–	157
2020 Q4	$24K	Buy	+500	New	+$23.4K	0.02%	142

Other funds holding OLMA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Kinloch Capital's OLMA Position: Q1 2021 in Review

Kinloch Capital sold out of Olema Pharmaceuticals (OLMA) in Q1 2021, closing a stake of 500 shares — an estimated $24K sold.

Kinloch Capital first reported a position in OLMA in Q4 2020 and held it in 1 quarter. The position peaked at $24K in Q4 2020. 74 funds tracked by Wall St. Rank hold OLMA as of Q1 2021.

Kinloch Capital reported no remaining Olema Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Kinloch Capital sold 500 Olema Pharmaceuticals shares in Q1 2021, an estimated $24K.
Kinloch Capital first reported a position in Olema Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Kinloch Capital's Olema Pharmaceuticals position peaked at $24K in Q4 2020.
74 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2021.

Based on Kinloch Capital's 13F filing for Q1 2021, filed 11 May 2021.